Structure elucidation of a PDE5 inhibitor detected as an illegal adulteration in a libido-boosting dietary supplement

References

• Ahn CY, Bae SK, Bae SH, Kang HE, Kim SH, Lee MG, Shin WG. 2011. Pharmacokinetics of sildenafil and its metabolite, N-desmethylsildenafil, in rats with liver cirrhosis and diabetes mellitus, alone and in combination. Xenobiotica. 41(2):164–174. doi:10.3109/00498254.2010.532885.
   PubMed Web of Science ®Google Scholar
• Doi T, Takahashi K, Yamazaki M, Asada A, Takeda A, Kiyota K, Tagami T, Sawabe Y, Yamano T. 2018. Characterization of a new illicit phosphodiesterase-type-5 inhibitor identified in the softgel shell of a dietary supplement. J Pharm Biomed Anal. 161:61–65. doi:10.1016/j.jpba.2018.08.031.
   PubMed Web of Science ®Google Scholar
• Francis SH, Corbin JD. 2005. Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol. 1(2):283–293. doi:10.1517/17425255.1.2.283.
   PubMedGoogle Scholar
• Gu Y, Hu Q, Sun J, Yu H, Pan H, Zhao X, Ji S. 2020. Isolation and identification of a new sildenafil analogue, hydroxycarbodenafil, found as an adulterant in a health supplement. J Pharm Biomed Anal. 185:113222. doi:10.1016/j.jpba.2020.113222.
   PubMed Web of Science ®Google Scholar
• Hsueh TY, Wu YT, Lin LC, Chiu AW, Lin CH, Tsai TH. 2013. Herb-drug interaction of epimedium sagittatum (Sieb. et Zucc.) maxim extract on the pharmacokinetics of sildenafil in rats. Molecules. 18(6):7323–7335. doi:10.3390/molecules18067323.
   PubMed Web of Science ®Google Scholar
• Huang YC, Lee HC, Lin YL, Tsai CF, Cheng HF. 2018. Identification of a new type tadalafil analogue in a supplement product. Food Addit Contam Part A. 35(7):1233–1237. doi:10.1080/19440049.2018.1459052.
   PubMed Web of Science ®Google Scholar
• Ichikawa-Kaji Y, Nakajima J, Kikkawa S, Ishizawa F, Nishiyama R, Kishimoto K, Uemura N, Satoh M, Suzuki J, Inomata A, et al. 2020. Identification of descarbonsildenafil in an adulterated dietary supplement and evaluation of its inhibitory activity for phosphodiesterase type 5 (PDE5). J Food Hyg Soc Jpn. 61(1):34–40. doi:10.3358/shokueishi.61.34.
   PubMed Web of Science ®Google Scholar
• Kee CL, Ge X, Gilard V, Malet-Martino M, Low MY. 2018. A review of synthetic phosphodiesterase type 5 inhibitors (PDE-5i) found as adulterants in dietary supplements. J Pharm Biomed Anal. 147:250–277. doi:10.1016/j.jpba.2017.07.031.
   PubMed Web of Science ®Google Scholar
• Lee HC, Lin YL, Huang YC, Tsai CF, Wang DY. 2018a. Identification of a new tadalafil analogue, N-3-hydroxypropylnortadalafil, in a supplement product. J Pharm Biomed Anal. 158:257–261. doi:10.1016/j.jpba.2018.05.049.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park HN, Jung A, Mandava S, Park S, Lee J, Kang H. 2018b. Isolation and characterisation of a novel sildenafil analogue adulterant, desmethylpiperazinyl propoxysildenafil, in a dietary supplement. Sci Justice. 58(6):447–454. doi:10.1016/j.scijus.2018.07.003.
   PubMed Web of Science ®Google Scholar
• Saenz de Tejada I, Frutos JA, Gaudo M, Florio V. 2002. Comparative selectivity: profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res. 14(Suppl 4):S20–S32.
   Google Scholar
• Sakamoto M, Minowa K, Kishimoto K, Nakajima J, Suzuki J, Moriyasu T, Fukaya H, Saito K. 2019. LC/Tribrid orbitrap analysis of phosphodiesterase-5 inhibitors and their analogs as adulterants in dietary supplements. J Food Hyg Soc Jpn. 60(4):96–107. doi:10.3358/shokueishi.60.96.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Suzuki J, Saito Y, Shimizu S, Kobayashi K, Nagashima M, Moriyasu T, Fukaya H, Saito K. 2018. Structural characterization of dimethyldithiodenafil and dimethylthiocarbodenafil, analogs of sildenafil. J Pharm Biomed Anal. 148:136–141. doi:10.1016/j.jpba.2017.09.025.
   PubMed Web of Science ®Google Scholar
• Sheldrick GM. 2015a. Crystal structure refinement with SHELXL. Acta Crystallogr C Struct Chem. 71(Pt 1):3–8. doi:10.1107/S2053229614024218.
   PubMed Web of Science ®Google Scholar
• Sheldrick GM. 2015b. SHELXT - integrated space-group and crystal-structure determination. Acta Crystallogr A Found Adv. 71(Pt 1):3–8. doi:10.1107/S2053273314026370.
   PubMed Web of Science ®Google Scholar
• Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, et al. 2003. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 425(6953):98–102. doi:10.1038/nature01914.
   PubMed Web of Science ®Google Scholar
• Venhuis BJ, de Kaste D. 2012. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J Pharm Biomed Anal. 69:196–208. doi:10.1016/j.jpba.2012.02.014.
   PubMed Web of Science ®Google Scholar
• Vicentini A, Liberatore L, Mastrocola D. 2016. Functional foods: trends and development of the global market. Ital J Food Sci. 28(2):338–351.
   Web of Science ®Google Scholar
• Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. 1999. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 29(3):297–310. doi:10.1080/004982599238687.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu Z, Chen T, Wang Z, Yang H, Zheng M, Ren J, Tian G, Yang X, Li L, et al. 2012. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. J Med Chem. 55(23):10540–10550. doi:10.1021/jm301159y.
   PubMed Web of Science ®Google Scholar
• Wang Z, Jiang X, Zhang X, Tian G, Yang R, Wu J, Zou X, Liu Z, Yang X, Wu C, et al. 2019. Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 Inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension. J Med Chem. 62(10):4979–4990. doi:10.1021/acs.jmedchem.9b00123.
   PubMed Web of Science ®Google Scholar
• Yun J, Shin KJ, Choi J, Kwon K, Jo CH. 2018. Identification and structural elucidation of a new sildenafil analogue, dithiopropylcarbodenafil, from a premixed powder intended as a dietary supplement. J Chromatogr Part B. 1072:273–281. doi:10.1016/j.jchromb.2017.11.029.
   PubMed Web of Science ®Google Scholar